Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Japan ETF (EWJ) vs Mesoblast Limited (MESO) Price & Performance

iShares MSCI Japan ETFTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

iShares MSCI Japan ETF vs Mesoblast Limited — how do they compare? iShares MSCI Japan ETF trades at $97.03, while Mesoblast Limited trades at $16.68 (market cap $2.21B). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.

EWJMESO
Sector
Broad Market / FactorTechnology
52-Week High
$96.97$20.96
52-Week Low
$77.93$12.88
Market Cap
$2.21B
Enterprise Value
$2.21B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Japan ETF

EWJ, the iShares MSCI Japan ETF, trades at $96.90, up 1.84% with a bullish technical signal from moving averages. Recent U.S.-Japan yen intervention and domestic economic stimulus efforts, including a food tax cut, are key drivers. The ETF's RSI_6 at 90.64 indicates overbought conditions, while support and resistance cluster near $96-$97.

Outlook is cautiously optimistic due to policy support and export benefits from yen strength, but risks include inflation pressures and tech sector volatility. The dividend of $0.50 scheduled for June 2026 adds income appeal, though current financial ratios are undisclosed, requiring scrutiny of underlying holdings.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

About iShares MSCI Japan ETF

EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.

Read more on EWJ

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO